Sentinel Therapeutics, Inc.
Sentinel is a clinical stage company developing a patented immunotherapy as a non-surgical alternative to treat skin cancer (BCC, melanoma).
Sentinel is developing ST1042 to treat skin cancers. This product has completed Ph 1-2a trials in the US and Europe and is in a 2a trial now. ST1042 has been shown to be safe and effective in treating forms of skin cancer. The next trial will be in BCC, the most common form of skin cancer. ST1042 will provide a non-surgical approach to treat BCC facial lesions where excision is not desirable. The market is over 2 MM procedures.